Basic Science Research
Our basic science research is comprised of our preclinical investigative teams led by internationally-recognized scientists focused on unlocking the power of the immune system to eliminate cancer. In partnership with their clinical colleagues, breakthroughs at the lab bench are translated to clinical trials and new therapies for cancer patients at Providence Cancer Center and beyond.
The major goal of the Antitumor T-cell Response Laboratory, led by Eric Tran, Ph.D., is to develop more effective T-cell based immunotherapies to treat patients with metastatic epithelial cancers. Read more.
The main focus of the Basic Immunology Laboratory, led by Andrew D. Weinberg, Ph.D., is to understand T cell activation during disease states. We have explored ways to manipulate the fate of antigen-specific T cells to enhance tumor-specific memory in hosts with cancer or down-regulate antigen-specific responses in autoimmune disease. Read more.
The long-term goal of the Cancer Immunobiology Laboratory, led by Hong-Ming Hu, Ph.D., is to understand how the immune system senses tumor cells and develop effective cancer vaccines and immunotherapy strategies. Read more.
The goal of Cancer Immunotherapy Laboratory, led by William L. Redmond, Ph.D., is to determine the molecular mechanisms by which tumors induce immune suppression. Ultimately, understanding how tumors escape destruction by the immune system will guide the development of novel anti-tumor therapies. Read more.
The Integrated Therapies Laboratory is a collaborative research effort between Michael J. Gough, Ph.D., and Marka R. Crittenden, M.D., Ph.D. It encompasses their overlapping research interest into the ability of cytotoxic therapy to provide large-scale cancer cell death in vivo, while modifying the profile of immune cells within the tumor. Read more.
The Molecular and Tumor Immunology Laboratory, led by Bernard A. Fox, Ph.D., hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine. Read more.
The Tumor Microenvironment Laboratory, led by Kristina H. Young, M.D., Ph.D., hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine. Read more.